Advertisements



Indian pharma firms renew focus; Dr Reddy"s, Cipla eye $100-bn China market

DRL looking to introduce anti-cancer drugs, while Cipla, Wockhardt planning to launch core therapies.....»»

Category: topSource: business-standardFeb 13th, 2018

Indian drug firms" growth slowed in 2017 on slow approvals, MNCs" caught up

GST rollout, more medicines being brought under price control, slow rate of drug approvals by NPPA hit Indian players, which control 80% of the domestic pharma market.....»»

Category: topSource: business-standardFeb 6th, 2018

Indian pharma companies under pressure on bourses, MNC peers fare better

Given the India focus, they will benefit more from domestic market growth, compared with Indian companies, which are currently facing pressure in their US businesses.....»»

Category: topSource: business-standardDec 11th, 2017

Infosys will focus on more innovation hubs in US: Nandan Nilekani

Infosys is planning to set up multiple innovation hubs in the US, the largest export market for Indian IT services firms with its first centre in Indiana planning to hire over 2,000 local engineers to serve customers in the countr.....»»

Category: topSource: business-standardNov 7th, 2017

R&D growth in pharma firms like Cipla, Dr Reddy"s outpaces revenue growth

Domestic pharma majors are betting big on R&D to drive future growth.....»»

Category: topSource: business-standardSep 28th, 2017

Indian drug firms reeling under US anti-trust row

Sun Pharma, Dr Reddy's Laboratories have also been dragged to the court by KPH Healthcare services.....»»

Category: topSource: business-standardJun 19th, 2017

Cipla to enter Brazil, China with emerging market focus

It is looking at further acquisitions to grow its speciality business in the US.....»»

Category: topSource: business-standardFeb 23rd, 2017

Pharma profits hit in US this quarter

Firms like Dr Reddy's and Cadila have seen US revenues dip due to heavy pressure on generics market.....»»

Category: topSource: business-standardOct 29th, 2016

US drags pharma profits, revenues this quarter

Firms like Dr Reddy's and Cadila have seen US revenues dip due to heavy pressure on generics market.....»»

Category: topSource: business-standardOct 29th, 2016

Domestic pharma firms zoom past MNCs in growth, market share

Indian firms enjoy 77% share, post 12.6% growth against 7.9% by MNCs, with superior penetration, brand recall, marketing.....»»

Category: topSource: business-standardOct 25th, 2016

The $ 240 bn biosimilar opportunity: Buddy up to succeed

Indian pharma companies will have to adopt strategy of collaboration (with global or domestic firms) to succeed in the market as cost of developing biosimilars are very high, says Pushpa Vijayraghavan.....»»

Category: topSource: business-standardOct 25th, 2016

China rules smartphone market amid boycott calls

Counterpoint Research data show Chinese firms' share of the Indian smartphone market has grown steadily this year.....»»

Category: topSource: business-standardOct 22nd, 2016

The cost of cheap drugs? Toxic Indian lake is "superbug hotspot"

Drugmakers in Medak, including large Indian firms Dr Reddy's Laboratories, Aurobindo Pharma and Hetero Drugs.....»»

Category: topSource: business-standardSep 29th, 2016

Indian, Chinese firms top AI investment, adoption in Asia: Forrester study

Asian enterprises see AI as a complete disruptive force across technology, industry, product, go-to-market, academic, and economic dimensions.....»»

Category: topSource: business-standardFeb 21st, 2018

Lego"s new way to boost motor skills, creativity in classrooms in China

The focus on learning, in a market notorious for its rigid exam-oriented education system and piles of homework, could help Lego in China as business elsewhere softens.....»»

Category: topSource: business-standardFeb 19th, 2018

Microsoft announces $500 million go-to market program for start-ups

Indian startup ecosystem is a focus area for us: Microsoft India MD.....»»

Category: topSource: business-standardFeb 15th, 2018

Pharma shares in focus; Cipla, Sun Pharma surge over 5%

At 02:59 PM; Nifty Pharma index, the largest gainer among sectoral indices, was up 3.6% as compared to 1.01% rise in the benchmark Nifty 50 index.....»»

Category: topSource: business-standardFeb 8th, 2018

Budget 2018: Govt targets rural voters with focus on agriculture, health

Farm incomes have fallen and Prime Minister Narendra Modi's administration has failed to deliver enough jobs to employ the mass of Indian youth joining the labour market.....»»

Category: topSource: business-standardFeb 1st, 2018

Why FDI policy stipulating joint audits may not help Indian firms

A section of the audit fraternity has been pitching with the govt to check the growing influence of international audit networks in Indian market.....»»

Category: topSource: business-standardJan 14th, 2018

70% duty on solar imports: How serious is China dominance in Indian market?

Business Standard looks at the authenticity of the claims of China's solar power might in India through the prism of numbers.....»»

Category: topSource: business-standardJan 11th, 2018

More USFDA approvals do not mean better margins for Indian "big pharma"

Indian pharma firms including their subsidiaries have received around 304 abbreviated new drug application approvals from the USFDA in 2017.....»»

Category: topSource: business-standardJan 10th, 2018